Alan Guttmacher last week took the controls as acting director at the National Human Genome Research Institute, after former director Francis Collins officially stepped down.
After serving as director of the institute for 15 years, Collins announced two months ago that he planned to leave NHGRI to dedicate some time to “writing, reflection, and exploration of other professional opportunities in the public or private sectors.”
Guttmacher is a pediatrician and medical geneticist. He has held leadership jobs at NHGRI for nearly a decade and has been deputy director for around six years.
Before he was deputy director, Guttmacher was NHGRI’s senior clinical advisor to the director and was director of the Office of Policy, Communications, and Education.
The National Institutes of Health will “conduct a broad search” for Collins’ replacement, NHGRI said last week, but details of that search process remain to be finalized.
"NHGRI and its collaborators, both at the NIH and throughout the biomedical research community, are moving ahead with our historic efforts to understand the intricacies of the human genome and how it functions,” Guttmacher said in a statement.
Celera has named Jean Amos Wilson to the post of president of laboratory operations at its Berkeley HeartLab subsidiary.
Amos Wilson formerly was senior director of genetic services at Sequenom, and before that she was scientific director of human genetics at Focus Diagnostics and director of molecular genetics at Specialty Laboratories. She is a fellow of the American College of Medical Genetics, a member of the board of directors of the American Board of Medical Genetics, and chair of the Clinical Laboratory Standards Institute.
CombiMatrix has appointed Colin Collins to the scientific advisory board of its subsidiary, CombiMatrix Molecular Diagnostics. Collins is associate professor of urology at the Cancer Research Institute and the department of molecular medicine at the University of California, San Francisco.
Collins’ research has led to the identification of genetic markers that have been used to risk-stratify cancer patients. He also invented a method of analyzing the structure of tumor genomes called end sequence profiling.